Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinelli, Giovanni, Iacobucci, Ilaria, Soverini, Simona, Palandri, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Baccarani, Michele
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721303/
https://www.ncbi.nlm.nih.gov/pubmed/19707322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721303/
https://www.ncbi.nlm.nih.gov/pubmed/19707322

Ejemplares similares